PFIZER LTD. - 500680 - Announcement under Regulation 30 (LODR)-Change in Management
Intimation regarding change in Senior Management Personnel.09-02-2024
09-02-2024
PFIZER LTD. - 500680 - Announcement under Regulation 30 (LODR)-Change in Directorate
Re-appointment of Ms. Meena Ganesh as an Independent Director09-02-2024
PFIZER LTD. - 500680 - Board Meeting Outcome for Re-Appointment Of Ms. Meena Ganesh As An Independent Director.
Re-appointment of Ms. Meena Ganesh09-02-2024
PFIZER LTD. - 500680 - Unaudited Financial Results For The Quarter Ended December 31, 2023.
Financial results for the quarter ended December 31, 2023.09-02-2024
PFIZER LTD. - 500680 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificates and issue of Letter of Confirmation.02-02-2024
PFIZER LTD. - 500680 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Company has received an Order on January 31, 2024 from the Deputy Commissioner, Government of Jharkhand, Commercial Tax Department, basis scrutiny of returns for the period 2014-15 under the Jharkhand Value Added Tax Act, 2005 for a penalty of Rs. 5000/-.01-02-2024
Pfizer, Glenmark Join Hands To Launch Skin Disease Drug In India
The product will be co-marketed under the brand names Jabryus and Cibinqo by Glenmark and Pfizer, respectively, it added.31-01-2024
Pfizer and Glenmark partner to introduce novel atopic dermatitis treatment in India
Atopic dermatitis is a debilitating form of chronic skin inflammation, characterised by severe itching and skin lesions31-01-2024
PFIZER LTD. - 500680 - Board Meeting Intimation for Board Meeting For Consideration And To Take On Record The Unaudited Financial Results For The Quarter Ended December 31, 2023.
PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2024 ,inter alia, to consider and approve and take on record the Unaudited Financial Results of the Company for the quarter ended December 31, 2023. Pursuant to the 'Pfizer Limited - Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders', the Trading Window of the Company was closed from December 31, 2023, till 48 hours after the results are made public on February 9, 2024. Request you to please take the above on record.31-01-2024
PFIZER LTD. - 500680 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding Loss of Share Certificates and issue of Letter of Confirmation.24-01-2024